Form 8-K - Current report:
SEC Accession No. 0001558370-21-007920
Filing Date
2021-06-02
Accepted
2021-06-02 07:02:20
Documents
15
Period of Report
2021-06-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20210602x8k.htm   iXBRL 8-K 37099
2 EX-99.1 plx-20210602xex99d1.htm EX-99.1 30011
3 GRAPHIC plx-20210602xex99d1001.jpg GRAPHIC 5582
4 GRAPHIC plx-20210602xex99d1002.jpg GRAPHIC 6293
  Complete submission text file 0001558370-21-007920.txt   214905

Data Files

Seq Description Document Type Size
5 EX-101.SCH plx-20210602.xsd EX-101.SCH 3246
6 EX-101.LAB plx-20210602_lab.xml EX-101.LAB 16160
7 EX-101.PRE plx-20210602_pre.xml EX-101.PRE 10905
8 EXTRACTED XBRL INSTANCE DOCUMENT plx-20210602x8k_htm.xml XML 4822
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 21987654
SIC: 2836 Biological Products, (No Diagnostic Substances)